Abstract: Histidine derivatives and processes of preparing the histidine derivatives. The histidine derivatives can be used to combat free radicals. The histidine derivatives may be used in cosmetic and/or dermatological compositions.

Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing dyes as contrast agents. Novel cyanine dyes that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These dyes are useful for imaging, diagnosis and therapy of various diseased states. Particularly, the molecules of the invention are useful for optical diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities, for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy.

Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing dyes as contrast agents. Novel cyanine dyes that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These dyes are useful for imaging, diagnosis and therapy of various diseased states. Particularly, the molecules of the invention are useful for optical diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities, for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy.

Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing dyes as contrast agents. Novel indocyanine dyes that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These dyes are useful for imaging, diagnosis and therapy of various diseased states. Particularly, the molecules of the invention are useful for optical diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities, for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy.

Abstract: A micro lysis and analysis process applying precise quantities of focused energy, such as light energy, to a precise microscopic area of a very small cell sample to activate an energy sensitive agent, such as a fluorescing agent, which permits measurement of cell fragility providing a means for determining the sensitivity of cells to particular chemicals, drugs, and/or diseases and the susceptibility and/or exposure of the cells to same.

Abstract: Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.

Abstract: The invention provides compounds comprising glycoprotein IIb/IIIa receptor-binding benzodiazepine derivatives covalently linked to metal ion chelators. The compounds of the invention may be labeled with a radionuclide such as 99mTc and used to image thrombi.

Abstract: A radioisotopic assessment of the integrity of the nose-brain barrier was performed on an anosmic patient by spraying an aliquot of a mixture of 99mTc-DTPA and hyaluronidase onto the olfactory mucosa with the patient's head positioned vertically and subsequently measuring the cerebral radioactivity. A significant rise in cerebral radioactivity was observed 5 minutes after introduction of the radioisotope. This simple technique will aid in assessing olfactory impairment from selected etiologies and also in testing the integrity of the nose-brain barrier. In view of the study of diseases such as viral encephalitis and Alzheimer's disease and others, the clinical implication of this method cannot be overemphasized. This principle may also facilitate developing novel pharmaceuticals for some brain diseases along with brain scintigraphy of novel modality.

Abstract: A method for visually demonstrating the effectiveness of an anti-bacteria attachment composition which comprises:a. treating skin with potential or known anti-bacteria attachment composition;b. contacting the said skin with a bacteria, resulting in the skin having bacteria attached to it;c. contacting the skin with a bacteria growth supporting medium having optionally therein or later optionally added a compound or mixture thereof which will assist in visually detecting a bacterial colony.

Abstract: Compounds of the formula: ##STR1## wherein X, Y, and R, independently of one another, is each a H; halogen, wherein said halogen is selected from the group consisting of .sup.123 I, .sup.124 I, .sup.125 I, .sup.131 I, .sup.75 Br, .sup.76 Br, .sup.77 Br, .sup.82 Br, .sup.18 F, or .sup.210 At; small alkyl, small alkenyl, or small alkynyl, any of which contains from one to about six carbon atoms and optionally having a carbon atom replaced by an O or S; or halogen substituted-small alkyl, halogen substituted-small alkenyl, or halogen substituted-small alkynyl wherein said compound contains at least one radioacitve halogen.The compounds bind to the serotonin transporter. Depending upon the choice of halogen substituent, the compounds are useful for PET or SPECT imaging, diagnosis and treatment of psychiatric disorders such as depression, anxiety, obsessive-compulsive disorder, and other conditions associated with defects of serotonin transporter function.

Abstract: A drug or other medication is incorporated into a candy and is molded onto a lollipop stick. A medicated lollipop is safely and conveniently stored by mounting the end of the lollipop stick remote from the medicated candy to the inner surface of a childproof cap. The lollipop then is inserted into a container, and the childproof cap is releasably locked with the open top of the container. The medicated lollipop can be accessed as needed merely by opening the container. Additionally, the medicated lollipop can be temporarily stored away from the container merely by converting the cap, and supporting the medicated lollipop by the cap.

Abstract: A nuclear medical drug for localize radiotheraphy of a tumor and methods for its preparation. The drug includes a radioactive ceramic or glass particle having biocompatiblity. Ceramic or glass particles prepared by traditional processes become radioactive particles with pure .beta.-particle-emitting radionuclides after being irradiated with an appropriate flux of neutrons. The radioactive particle with suitable particle size can then be dispersed into a contrast medium for injection or can be implanted by operation.

Abstract: This invention relates to new bifunctional chelating agents with intermittent chalcogen atoms, pharmaceuticals containing these compounds, their use in radiodiagnostics and radiotherapy, and methods for the production of these compounds.The compound according to the invention has the general formula (I)M--Lwherein M represents a radionuclide of Tc or Re and L a ligand of the general formula (II)B--CO--CR.sup.1 R.sup.2 --A--CR.sup.3 R.sup.4 --CO--D (II)These new, bifunctional chelating agents with intermittent chalcogen atoms and their coupling products with compounds that accumulate specifically are suited for producing radiopharmaceuticals for diagnostic and therapeutic purposes.

Abstract: Dioxetanes that can be triggered by bases are provided which can be used to detect bases in organic solvents, aqueous preparations and detect gaseous bases in the atmosphere. The dioxetanes can be used to detect the release of bases from various labels, as a means to detect the presence of a base released by physical or natural processes, to calibrate light measuring apparatus and to determine the amount of reducing or oxidizing agent present in the base.

Abstract: A metalorganic complex of the formula:MA.sub.Y Xwherein:M is a y-valent metal;A is a monodentate or multidentate organic ligand coordinated to M which allows complexing of MAY with X;y is an integer having a value of 2, 3 or 4;each of the A ligands may be the same or different; andX is a monodentate or multidentate ligand coordinated to M and containing one or more atoms independently selected from the group consisting of atoms of the elements C, N, H, S, O and F.The metal M may be selected from the group consisting of Cu, Ba, Sr, La, Nd, Ce, Pr, Sm, Eu, Th, Gd, Th, Dy, Ho, Er, Tm, Yb, Lu, Bi, Tl, Y, Pb, Ni, Pd, Pt, Al, Ga, In, Ag, Au, Co, Rh, Ir, Fe, Ru, Sn, Li, Na, K, Rb, Cs, Ca, Mg, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, and W. A may be selected from the group consisting of .beta.-diketonates and their sulfur and nitrogen analogs, .beta.-ketoesters and their sulfur and nitrogen analogs, cyclopentadienyls, alkyls, perfluoroalkyls, alkoxides, perfluoroalkoxides, and Schiff bases.

Abstract: .sup.99m Tc complexes of formula L.sub.n Tc.dbd.NR, L.sub.n Tc--N.dbd.NY, or L.sub.n Tc--(N.dbd.NY).sub.2 wherein each L is independently a monodentate or multidentate ligand;Y is a substituted or unsubstituted aryl group or substituted or unsubstituted alkyl group;R is Y or the grouping --NR.sup.1 R.sup.2 ;n is 1-4;where at least one of R or Y is combined with one or more of the L groups; R.sup.1 and R.sup.2 are H, substituted or unsubstituted aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and are the same or different, provided that both are not hydrogen.

Abstract: Compounds and samples may be screened for estrogenic, androgenic, and thyroid hormone activity simultaneously, by administering the compound or sample to larval amphibians or tissue obtained therefrom, particularly Hyperolius argus, prior to the end of metamorphosis, and observing developmental differences between the test amphibians and normal development for said amphibians.

Abstract: The invention pertains to compounds which specifically bind radionuclides, and to methods of making radionuclide complexing compounds. In one aspect, the invention includes a radionuclide delivery system comprising: a) a calix[n]arene-crown-[m]-ether compound, wherein n is an integer greater than 3, and wherein m is an integer greater than 3, the calix[n]arene-crown-[m]-ether compound comprising at least two ionizable groups; and b) an antibody attached to the calix[n]arene-crown-[m]-ether compound.

Abstract: A method of generating an image of a human or non-human animal body which comprises administering to said body a physiologically tolerable contrast enhancing amount of a non-cluster type bismuth compound, and methods of treating gastrointestinal disorders using the same. Diagnostic imaging contrast media comprising non-cluster type bismuth compounds are also disclosed, together with novel covalent non-cluster type bismuth compounds.

Abstract: The invention provides detectably-labeled compounds of formula (I): ##STR1## wherein A, B, C, D, E, F, R, X, Y and Z have any of the meanings given in the specification, and their pharmaceutically acceptable salts, are useful in competitive assays to assay for the presence of .sigma.2 receptors. Also disclosed are pharmaceutical compositions containing such a compound of formula (I), methods for their use and intermediates useful for preparing such compounds of formula (I).